ArticleTranslational lung cancer research2025
Computer-aided quantitative stromal analysis: a comprehensive investigation of its prognostic significance in lung squamous cell carcinoma.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The tumor-stroma ratio (TSR) has been validated as an independent prognostic factor across multiple cancer types, including lung squamous cell carcinoma (LUSC), in which a stroma-rich phenotype is generally linked to poor outcomes. However, traditional manual TSR assessment is subjective and has limited reproducibility. This study aimed to investigate the clinical utility of computer-aided (CA) quantitative stromal analysis in LUSC, elucidate the correlation between TSR and clinicopathological features, and provide a theoretical basis for precision diagnosis and treatment. Methods: There were 189 patients with primary LUSC diagnosed between 2015 and 2020 included in a retrospective cohort. Using automated analysis techniques in conjunction with whole-slide imaging (WSI), a quantitative evaluation of the TSR was carried out automatically. Meanwhile, the TSR was also evaluated manually. Based on the median TSR value, patients were categorized into cohorts that were either stroma-poor (TSR-L) group or stroma-rich (TSR-H) group. Using Cox regression models and Kaplan-Meier survival analysis, prognostic significance was tested. In addition, the consistency between the results of manual evaluation and those of CA evaluation was analyzed. Results: The median CA-TSR score was 0.34. Patients in the TSR-H group demonstrated significantly worse overall survival (OS) and disease-free survival (DFS) (both P<0.001), which corresponded with pleural invasion (P=0.03) and advanced pathological staging. The area under the curve (AUC) for OS demonstrated the superior predictive accuracy of CA-TSR over manual scoring (0.651-0.7 Conclusions: CA-driven quantitative TSR analysis enables objective and efficient assessment of the stromal ratio in LUSC. The CA-TSR score serves as an independent prognostic predictor, significantly enhancing survival prediction accuracy compared to conventional methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.